Fourpath Capital Management LLC Purchases 876 Shares of AbbVie Inc. (NYSE:ABBV)

Fourpath Capital Management LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 13.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,426 shares of the company’s stock after acquiring an additional 876 shares during the quarter. Fourpath Capital Management LLC’s holdings in AbbVie were worth $1,320,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Optas LLC boosted its position in shares of AbbVie by 6.8% during the 4th quarter. Optas LLC now owns 4,824 shares of the company’s stock worth $857,000 after purchasing an additional 309 shares in the last quarter. Holistic Planning LLC boosted its holdings in AbbVie by 27.6% in the fourth quarter. Holistic Planning LLC now owns 1,354 shares of the company’s stock worth $241,000 after acquiring an additional 293 shares in the last quarter. Hodges Capital Management Inc. grew its stake in AbbVie by 15.8% in the fourth quarter. Hodges Capital Management Inc. now owns 40,989 shares of the company’s stock valued at $7,283,000 after acquiring an additional 5,587 shares during the period. EQ Wealth Advisors LLC acquired a new position in shares of AbbVie during the fourth quarter worth approximately $231,000. Finally, One Wealth Advisors LLC lifted its holdings in shares of AbbVie by 73.2% in the 4th quarter. One Wealth Advisors LLC now owns 2,378 shares of the company’s stock worth $423,000 after purchasing an additional 1,005 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Up 3.4 %

Shares of NYSE ABBV opened at $190.20 on Tuesday. The business’s fifty day moving average price is $176.57 and its 200-day moving average price is $185.13. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32. The stock has a market capitalization of $336.12 billion, a PE ratio of 79.25, a P/E/G ratio of 1.84 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter in the previous year, the company posted $2.79 earnings per share. On average, equities research analysts anticipate that AbbVie Inc. will post 12.26 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ABBV shares. BMO Capital Markets boosted their price target on shares of AbbVie from $208.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday. Bank of America restated a “neutral” rating and issued a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Leerink Partnrs upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Sanford C. Bernstein assumed coverage on AbbVie in a research note on Thursday, October 17th. They issued a “market perform” rating and a $203.00 price objective for the company. Finally, Morgan Stanley lifted their target price on AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a research report on Monday. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.